The ability of dendritic cells (DCs), genetically modified with one of two types of plasmid DNA vaccines to stimulate lymphocytes from normal human donors and to generate antigen-specific responses, is compared. The first type, also called ''secreted'' vaccine (sVac), encodes for the full length of the human prostate-specific antigen (PSA) with a signal peptide sequence so that the expressed product is glycosylated and directed to the secretory pathway. The second type, truncated vaccines (tVacs), encodes for either hPSA or human prostate acidic phosphatase (hPAP), both of which lack signal peptide sequences and are retained in the cytosol and degraded by the proteasomes following expression. Monocyte-derived dendritic cells are transiently transfected with either sVac or one of two tVacs. The DCs are then used to activate CD25 þ -depleted or nondepleted autologous lymphocytes in an in vitro model of DNA vaccination. Lymphocytes are boosted following priming with transfected DCs, peptide-pulsed DCs or monocytes. Their reactivity is tested against tumor cells or peptide-pulsed T2 target cells. Both tVacDCs and sVacDCs generate antigen-specific cytotoxic T-cell responses. The immune response is restricted towards one of the three antigen-derived epitopes when priming and boosting is performed with sVacDCs. In contrast, tVac-transfected DCs prime T cells towards all antigen-derived epitopes. Subsequent repeated boosting with transfected DCs, however, restricts the immune response to a single epitope due to immunodominance. While CD25 þ cell depletion prior to priming with sVacDCs alleviates immunodominance, cotransfection of dendritic cells with GITR-L does so in some but not all cases.
I n a previous study, 1 we found that dendritic cells transfected with products that were cytosolically retained and degraded in the proteasomes, primed autologous T cells to multiple epitopes. Priming with sVacDCs, however, restricted the immune response to one of the epitopes due to immunodominance and the latter was alleviated if anti-CTLA-4 antibodies were present. We wanted to extend these observations to other tumorassociated antigens such as prostate-specific antigen (PSA) and prostate acidic phosphatase (PAP), as well as to study the effect that the removal of CD4 þ CD25 þ cells prior to priming may have on immunodominance development. Both PSA and PAP are currently used as targets for immunotherapy of cancer. [2] [3] [4] On the other hand, gene-based vaccination in its current mode of application is effective in breaking tolerance to a selfantigen, but the response appears to be narrow and restricted to few of the potential epitopes. For example, the postvaccination T-cell response of some of the HLA A2 patients from the clinical trial performed by us 5 was directed against only two of the potential 4 PSMA peptide motifs that had high affinity for binding (M Mincheff, unpublished) . Immunodominance is a natural mechanism for control that ensures the tight specificity of the immune reaction and prevents untoward autoimmunity, but it also carries the risk of inefficient immune surveillance in cases such as cancer, where mutations of the epitope or downregulation of MHC alleles occur. [6] [7] [8] Malignant transformation and tumor progression are frequently associated with loss of HLA class I antigens. For example, a recent review of the literature 9 has reported that B15 and 55% of surgically removed primary and metastatic melanoma lesions, respectively, are not stained in immunohistochemical reactions by monoclonal antibodies to monomorphic determinants of HLA class I antigens. Loss or reduced HLA class I antigen expression enables tumor cells to evade the host's immune response 6, 7, [10] [11] [12] and downregulation of HLA class I antigens in metastases from patients with malignant melanoma has been associated with poorer prognosis. 13 Immunodominance, therefore, presents a problem in vaccinology. 8, 14, 15 New vaccines and/or new methods of immunizations need to be developed for those instances. These hopefully will raise responses to subdominant determinants so that the selection of tumor escape variants that fail to express immunodominant epitopes will be prevented. 8 Numerous factors combine to establish an immunodominance hierarchy. 16 Preliminary results from our laboratory suggest that the enhanced priming to subdominant epitopes by CTLA-4 inhibition is at least partially mediated through the inhibition of CD4 þ CD25 þ T-cell function. These CD4 þ T cells are a minor subpopulation (10%) that coexpresses the IL-2 receptor a-chain (CD25) 17 and they can prevent both the induction and effector function of autoreactive T cells. [18] [19] [20] Additionally, they suppress polyclonal T-cell activation in vitro by inhibiting IL-2 production. 21 Very little is known of the physiologic regulation of CD4 þ CD25 þ T cells in vivo. 22 Recent reports suggest that glucocorticoid-induced tumor necrosis factor receptor (GITR), also known as TNFRSF18-a member of the TNF-nerve growth factor receptor gene superfamily-is predominantly expressed on CD4 þ CD25 þ T cells 22, 23 and stimulation of GITR abrogates CD4 þ CD25 þ T-cell-mediated suppression. 23 The gene encoding the natural ligand of human GITR has been cloned and characterized. It is called GITR-ligand (GITR-L), a human activation-inducible TNF receptor (AITR) ligand, or TL6. Expression of the GITR-L is detected in immature and mature splenic dendritic cells. GITR-L binds GITR expressed on HEK 293 cells and triggers NF-kappa B activation. Functional studies reveal that soluble CD8-GITR-L prevents CD4 þ CD25 þ regulatory T-cell-mediated suppressive activities. 24 Would CD25 þ T-cell depletion prior to priming alleviate immunodominance? If CD25 þ cells suppress priming of subdominant T-cell clone, could immunodominance be restricted by GITR signaling? Could this be achieved by enhanced GITR-L coexpression during reimmunization?
The following experiments were designed to test these hypotheses in an in vitro immunization system with human cells.
Materials and methods
All human cellular materials used in these experiments were obtained following informed consent through protocols approved by the local Committee for Bioethics (Bulgaria) or the Investigational Review Board (IRB) at George Washington University Medical Center in Washington, DC. Use of recombinant DNA was approved by the local IRAC committees.
htPAP-, hGITR-L-, hsPSA-and htPSA plasmids construction hPAP was obtained by RT-PCR of total RNA from LNCaP cells using TriPure RNA/DNA isolation reagent and Titan RT-PCR kit (Roche). The first cDNA strand was synthesized using hPAP-specific reverse primer (5 0 -GAGATCTCTGTGCACACTAATCTGTA-3 0 ). Amplification was performed using the direct primer 5 0 -TCCTAACTCCTGCCAGAAACAGCTCT-3 0 and the same reverse primer. After initial denaturation, step (2 minutes, 941C) and the first 10 cycles (30 seconds at 941C, 25 seconds at 601C, 45 seconds at 721C) the extension time was progressively incremented by 15 seconds after each of the additional 20 cycles. The gel-purified PCR product was cloned into a pCR2.1 vector (Invitrogen) and several clones were sequenced. All of them contained silent or nonsilent substitutions. Two clones were selected for further work: 150.16 (no substitution in the 5 0 -region) and 150.20 (no substitution in the 3 0 -region). Truncated hPAP (hPAP-T) was obtained by PCR of the clone 150.16 containing no substitution in the region between the end of signal peptide (position 97 on cds) and a single SfuI site (position 311 on cds). The direct primer (CGGCGGGGTACCATGGAGTTGAAGTTTGTGAC TTTGGTG) introduces a KpnI site and a Kozak sequence (underlined). The first amino acid next to the signal peptide (Lys) was replaced by Met (bold italic). The reverse primer (5-GGCTGCCAGAGTAGGATAGGA TTC-3 0 ) anneals to the region downstream of a single SfuI site. The PCR product was digested with KpnI and SfuI endonucleases, gel purified, and subcloned by KpnISfuI sites into the clone 150.20 replacing its 5'-region that has substitutions and signal peptide sequence. The correctness of the resulting clone was checked by sequencing.
Finally, the hPAP-T sequence was transferred by BamHI-XbaI sites from the pCR2.1 vector to the mammalian expression vector p147 (see below).
Human GITR-L was obtained by RT-PCR of total RNA from HuVec cells using specific primers (direct: 5 0 -GGTACCATGTGTTTGAGCCACTTGGAAAATATG CC-3 0 ; reverse: 5 0 -CTAGGAGATGAATTGGGGATTT GC-3 0 ). The PCR product (544 bp long) was cloned into a pCR2.1 vector and several clones were sequenced. All of them contained mutations. hGITR-L insert from one of the clones was transferred by HindIII-XhoI sites into the vector p147 and the mutations were corrected using QuickChange Site Directed Mutagenesis kit (Stratagen). The sequence of the final clone is identical to hGITR-L genebank entry AF125303.
The hPSA-containing plasmid was kindly provided by Jan Geliebter, New York Medical College, Department of Microbiology and Immunology, Valhalla, NY, USA. The clone represents the complete hPSA cDNA sequence included in a pCDNA3 (Invitrogen) vector. The clone contains two nonsilent nucleotide substitutions: C-A at cds position 289, and G-A at cds position 406 leading to substitutions Pro97 by Thr and Val136 by Met, respectively. These mutations do not affect the generation of PSA-derived 9-mer epitopes with high affinity for binding to HLA A201 as predicted by the computer-based algorithm available at http://bimas.cit.nih.gov/.
To obtain a 5 0 -truncated form of hPSA (hPSA-T) that lacks a signal peptide, a PCR of the hPSA region from the end of signal peptide (cds position 52) to the end of cds was performed. A direct primer (GCGGCCGCC GCCACCATGGCACCCCTCATCCTGTCTCGG) introduced a NotI recognition site and a Kozak sequence (underlined) as well as the start methionine (bold italic). A reverse primer (5 0 -GTTTAAACTCAGGGGTTGGCCA CGATGGTGTC-3 0 ) introduced the PmeI site (underlined) just next to stop codon. The PCR product was cloned into a pCR2.1 vector and sequenced. The hPSA-T was then excised from the pCR2.1 vector by cutting with NotI þ PmeI, gel purified and ligated with pVAX-1 mammalian expression vector (Invitrogen) by NotI and XhoI sites. The last one was blunted with Klenow enzyme in the presence of excess of dNTP. Consequently, hPSA-T was transferred by BamHI-XbaI sites to the mammalian expression vector p147.
The mammalian expression vector p147 represents a modified pCDNA3 vector (Invitrogen) in which the ampicillin resistance gene was replaced with kanamycin resistance gene. The replacement was performed by ligation of BclI-BspHI fragment from pVAX-1 plasmid with BglII-BspHI fragment of plasmid pCDNA3. The former fragment contains kanamycin resistance gene, the last one includes all elements of pCDNA3 vector except the ampicillin resistance gene.
The plasmid-DNA product specifications include endotoxin content below 0.1 EU/mg of DNA; 490% of covalently closed circle DNA, lack of detectable amounts of bacterial RNA, genomic DNA or ssDNA as determined by agarose-gel electrophoresis; less than 10 mg of protein per 1 mg of plasmid DNA as determined by colorimetric assay (Bio-Rad, Hercules, CA).
COS-1 transfection
Expression of PSA and PAP constructs (sVacs or tVacs) was performed in COS-1 cells (ATCC). A stably transfected AT3B-1 (ATCC) cell line which secretes PSA was obtained. Monolayers were transfected with FuGENE 6 transfection reagent (Roche) and assayed for PSA or PAP production by Western blot. COS-1 or AT3B-1 cells were seeded in six-well tissue culture plates (Nunc, Denmark) at 1.5 Â 10 5 cells/well and grown to 50-70% confluence in DMEM supplemented with 25 mM HEPES (pH 7.5), 1 mM sodium pyruvate, 3.7 g/l sodium bicarbonate, 100 mg/ml penicillin, 100 mg/ml streptomycin, 0.25 mg/ml amphotericin B and 10% (v/v) of heatinactivated fetal bovine serum. COS-1 or AT3B-1 cells were transfected with 1.5 mg of plasmid DNA precondensed with 4.5 ml of FuGENE6 reagent in serum-free DMEM for 30 minutes at room temperature. Cells were then grown for 72 hours in complete DMEM and then harvested.
In the proteasome inhibition studies, lactacystin (Sigma) was added to the culture media (final concentration 10 mM) 24 hours before harvesting.
Cells were harvested by gentle scraping, washed twice with 2 ml of cold PBS and 0.25 ml cold lysing buffer (0.5 M NaCl, 1% Triton X-100, 0.2% Tween-20, 50 mM HEPES, pH 7.0) was added to each well. Lysates were transferred to Eppendorf tubes and homogenized by repeated pipetting on ice.
For detection of secreted PSA, the serum-containing DMEM was removed 48 hours after transfection, the cells were washed twice with 2 ml of PBS, serum-free DMEM (2 ml/well) was added and cells were incubated for additional 24 hours in the six-well plates. After collection of the medium, the cell debris was removed by centrifugation (35,000 g, 20 minutes) and supernatants were concentrated with Centricom centrifuge filtering device (Millipore) and then stored at À301C until further use.
Electrophoresis and immunoblotting
Immunoblotting and electrophoretic assays of cell lysates and culture supernatants were performed using NuPage BioTris electrophoretic system (Invitrogen). Protein samples in loading buffer were heated at 701C for 10 minutes and loaded on 10% Bis-Tris gels. After electrophoresis, the proteins were electro-transferred onto nitrocellulose membrane and blocked with 1% casein in TBS/T for 40 minutes. The membranes were probed with poly-or monoclonal anti-PSA or PAP Abs (see below) for 1 h at RT. Detection was performed using goat anti-rabbit or anti-mouse IgG conjugated with HRP (Sigma) and visualized with WestPico Super Signal Chemo luminescent Substrate (Pierce) in accordance with the manufacturer's recommendations.
Anti-human PSA monoclonal antibodies sc-7316 and sc-7638 were obtained from Santa Cruz Biotechnologies, Inc. (Santa Cruz, CA). Purified PSA protein was obtained from International Immuno-Diagnostics, Foster City, CA. Anti-human PAP monoclonal antibody (mouse, IgG1), clone Pase/4LJ, was obtained from Acris Antibodies GmbH (Germany).
Flow cytometry analysis
Antibodies used to phenotype the cells were anti-CD1a, anti-HLA-DR-PE, anti-CD80-PE, anti-CD86-PE, anti-CD83-FITC, anti-CD54-PE, anti-HLA-ABC-FITC, anti-CD14-FITC, anti-CD8-PE, anti-CD4-PE, anti-CD69-FITC (PharMingen, San Diego, CA), and anti-CD3-PerCP (Becton Dickinson, San Jose, CA). Anti-GITR-L antibodies (clones 109114 and 109117) and anti-GITR (clone 110416) were supplied by R&D Systems Inc.; Minneapolis, MN 55413, USA. For HLA-A2 Typing, aliquots of PBMC from buffy coats of healthy donors were tested with the FITC-labeled anti-HLA A2 antibody BB7.2 (Becton Dickinson). For staining, 10 5 cells were suspended in 100 ml of PBS and were incubated with 10 ml of the antibodies for 20 minutes on ice. Flow cytometric analysis was performed on a FACS Calibur (Becton Dickinson).
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Phenotyping of CD25 þ regulatory T cells (TR)
Briefly, fresh or frozen PBMC were washed once in phosphate-buffered saline (PBS) containing 1% bovine serum albumin (BSA) (Sigma-Aldrich, St Louis, MO) and stained with antibodies for CD3 (peridinin chlorophyll protein; PerCP), CD4 (fluorescein isothiocyanate; FITC), CD8 (allophycocyanin; APC), CD25-FITC or -phycoerythrin (PE), CD38-APC or -PE, and/or HLA-DR-APC (BD BioSciences, San Jose, CA, and BD BioSciences PharMingen, San Diego, CA) for 20 minutes at 41C. The cells were then washed twice with PBS containing 1% BSA, fixed in 1% paraformaldehyde, acquired on a flow cytometer (FACSCalibur; BD BioSciences), and analyzed using FlowJo software (Tree Star, San Carlos, CA).
Cell cultures
Cell cultures from peripheral blood mononuclear cells were maintained in research grade serum-free AIM-V medium (Invitrogen, Carlsbad, CA). The human prostate cancer cell line LNCaP was purchased from ATCC and was maintained in RPMI supplemented with 10% FCS (Life Technologies Inc., Rockville, MD), 2 mM Lglutamine, 50 U/ml penicillin and 50 mg/ml streptomycin (complete medium; CM). The human T2 cell line is transporter associated with antigen processing (TAP) deficient, resulting in inefficient loading of human leukocyte antigen class I molecules with endogenous peptides. 25 As a consequence, the HLA-A0201 molecules of T2 cells can be efficiently loaded with exogenous peptides. The T2 cell line was purchased from ATCC and maintained in IMDM supplemented with 20% FBS (Life Technologies Inc., Rockville, MD).
For T-cell stimulation, the leukocyte fraction was collected by leukapheresis and mononuclear cells were separated on a density gradient. Cells were resuspended in serum-free AIM-V medium at 2 Â 10 7 /ml in culture flasks for 2 hours in a humidified incubator at 371C. The nonadherent T-cell enriched fraction (later in the text referred to as ''T cells'') and part of the adherent cells were harvested and frozen for future use.
Depletion of CD25
þ cells CD25 þ cells were purified with MACS CD25 MicroBeads (Miltenyi Biotec, Auburn, CA). Briefly, the nonadherent T-cell-enriched fraction (T cells) was washed twice in PBS containing 0.5% BSA and 2 mM EDTA, resuspended in 80 ml of PBS containing 0.5% BSA-2 mM EDTA and 20 ml of MACS CD25 MicroBeads per 10 7 total PBMC, and incubated for 15 minutes at 6-121C. The cells were washed twice in PBS containing 0.5% BSA and 2 mM EDTA and applied to a magnetic column on a MidiMACS separation unit (Miltenyi Biotec). CD25 þ and CD25-T-cell fractions were collected. The CD25 þ cell fraction contained 490% CD4 þ T cells. In some experiments the CD25 þ cell fraction was purified to 499% CD4 þ T cells by cell sorting after staining with monoclonal antibodies to CD3 and CD4 (FACSvantage; BD Biosciences) and frozen for add-back experiments. In other experiments, CD4 þ CD25 þ T cells were stimulated for 48 hours with plate-bound anti-CD3 monoclonal antibody and IL-2 and used for staining with anti-GITR antibody.
Generation of monocytes-derived dendritic cells
The rest of the adherent cells were differentiated into DC by culture in serum-free AIM-V medium with IL-4 (PeproTech, Rocky Hill, NJ) and GM-CSF (Oncology Supplies Inc. (Dothan, AL) for 6 days. The nonadherent cells were harvested at that time and used for transfection. Transfection was performed using the Nucleofectort device and transfection kit (Amaxa GmbH, Cologne, Germany). The green fluorescence protein (GFP) transfection efficiency of human DCs after Nucleofectort transfection was 3278.8% (n ¼ 5). Following transfection, dendritic cells were resuspended in serum-free AIM-V medium and matured with TNF-a (Becton Dickinson Inc., Bedford, MA) at 371C for 24 hours. Following maturation, the DCs were resuspended in AIM-V medium at 1 Â 10 5 cells/ml. Treatment of tPSMA-and sPSMA-transfected DCs with TNF-a triggers a coordinate series of phenotypic changes, resulting in an upregulation of costimulatory molecules (CD80, CD86, CD40) and HLA class II antigens. 1 
In vitro generation of CTL responses
For T-cell stimulation, the T cells with or without prior CD25 þ -depletion, were thawed, washed, resuspended in AIM-V medium and added to the DC suspension so that the final concentration of the T cells was 1 Â 10 6 cells/ml (T cell/DC ratio ¼ 10:1). The cell suspension was then distributed into 24-wells plates (1 ml/well; Costar plates) and cultured at 371C.
In some experiments CD4 þ CD25 þ T cells were added back to the stimulated T cells. In those, 0.25 Â 10 6
CD4
þ CD25 þ T cells were added to each well (responder T cells/CD4 þ CD25 þ T-cell ratio ¼ 4:1) at different time points following priming.
After 3 days, the medium was removed and the T cells were cultured from that moment in serum free AIV-M medium supplemented with human IL-2 (20 U/ml) and human IL-7 (10 U/ml) (PeproTech, Rocky Hill, NJ). Cells were additionally stimulated with autologous PSMAtransfected DCs (stimulator:effector ratio of 1:10) or with peptide-pulsed autologous monocytes (stimulator:effector ratio of 1:1) twice, 8 days apart.
For pulsing with peptides, monocytes were resuspended at 10 6 /ml in serum-free RPMI-1640 with L-glutamine and penicillin/streptomycin. Peptide was added to a final concentration of 0.05 mg/ml and the cells were incubated for 4 hours at 371C in a controlled CO 2 humidified incubator. The cells were then washed twice with serumfree medium, irradiated (1500 rad) and used for boosting in IL-2 and IL-7 containing medium.
For peptide pulsing of T2 cells, we initially performed peptide-binding assays. For that purpose, T2 cells were incubated (10 5 After 20 days of culture, effector cells were harvested without further separation for microcytotoxicity assays. The cells were analyzed by flow cytometry and 83% þ /À 10% of them were CD3 þ and B45% of them (when primed with the sPSA DCs) and B60% of them (when primed with the tPSA DCs) were CD3 þ CD8 þ (data not shown).
Selection of HLA-A2-binding PSA-and PAP-peptides
For the present study, the amino-acid sequence of the truncated (no-leader sequence) PSA (AA 25-161) and PAP (AA 33-386) were analyzed for the existence of 9-amino-acid peptides predicted to bind to HLA-A201, the most common human MHC class I allele, using the computer-based algorithm (http://bimas.cit.nih.gov/) ( Table 1 ). Three 9-mer peptides from each sequence that contained peptide-binding motifs for the HLA A201 class I molecule were identified.
Cytotoxicity testing
Cytotoxicity against LNCaP cells or against peptidepulsed T2 cells (both HLA A2-positive) was tested after 20 days of culture and compared to a control cell line that did not express PSA or PAP. Cytotoxicity was tested using the JAM test. 26 Briefly, target or control cells were grown overnight with 3 H-thymidine, then washed, resuspended in CM and used in 4-hour cytotoxicity test. The killing was detected as a fall in counts per minute due to DNA fragmentation in cell samples undergoing apoptosis. All of the E:T ratios were tested in triplicate. Spontaneous cytotoxicity was determined in medium alone without effector cells.
Unlabelled K562 cells (no MHC expression and sensitive to natural killer cell-mediated lysis) were included at 50 Â the target cell number to inhibit nonspecific lysis. Control experiments involved the Malme M3 melanoma cell line, which is also HLA A2 positive.
Cell lines
The human LNCaP (CRL-1740), T2 (CRL-1992), Malme 3 M (HTB-64), COS-1 (CRL-1650) and AT3B-1 (CRL-2375) cell lines were purchased from ATCC and were maintained according to ATCC instructions. H-thymidine was purchased from ICN Biomedical Inc (Irvine, CA).
Cytokines and

Statistics and epitope binding predictions
Analysis of cytotoxicity data were performed using twotailed Student's t-tests assuming equal variance. We used the predictive algorithm from the Bioinformatics and Molecular Analysis Section of the NIH (''BIMAS'') that was developed by Parker et al, 27 ranking potential MHC binders according to the predictive one-half-time disassociation of peptide/MHC complexes for epitope binding prediction.
Peptide synthesis and purification
Peptides were custom synthesized and purified by Sigma Genosys (The Woodlands, TX).
Results
COS-1 cells transfected with tPSA, sPSA or GITR-L plasmids express the encoded product
Following transfection with sPSA plasmid, the encoded product is N-glycosylated and could be detected intraand extracellularly -that is, is secreted (Fig 1a and b) . The product expressed following transfection with the tPSA plasmid is not glycosylated, but is retained in the cytosol and rapidly degraded in the proteasome. Similarly to transfection with another ''truncated'' gene-based vaccine, 1 the product could be detected following proteasomal inhibition with lactacystin. COS-1 cells transfected with GITR-L stain positively with antibodies specific for the GITR-L (Fig 2) . tVacDCs ( tPSA DCs, tPAPDCs) and sVac DCs (sPSA DCs) prime and support development of T cells that are cytotoxic against LNCaP cells
The T-cell-enriched fraction from each leukapheresis was primed and then boosted twice, at 8-day intervals with autologous PSA-transfected DCs. Their cytotoxicity was then tested against LNCaP cells or control Malme M3 melanoma cells. Both tVacDCs and sVacDCs primed and supported development of T cells that are cytotoxic against LNCaP cells (Fig 3) . Recently, we found that dendritic cells transfected with a fragment of the human prostate-specific membrane antigen that was cytosolically retained and degraded in the proteasome (tPSMA DCs), primed autologous T cells to multiple epitopes. 1 To extend these observations to other prostate antigens such as PSA and PAP, we primed the T-cell-enriched fraction from leukapheresis with either tPSA DCs, sPSA DCs or tPAP DCs and boosted them twice, at 8-day intervals, with autologous monocytes pulsed with one of several PSA or PAP-derived peptides (Table 1) . At 20 days after priming, cytotoxicity was tested against T2 cells pulsed with the same peptide used for boosting. Unlike dendritic cells pulsed with the sPSA plasmid, tVac DCs prime T cells to all PSA-or PAPderived peptides in all five donors tested (Fig 4) . DCs or monocytes, loaded with PSA peptides, support development of T-cell effectors with similar efficacy (Fig 4) .
Repeated boosting with transfected DCs restricts the response towards one immunodominant epitope
Previously, we found that boosting with polyepitope expressing DCs restricts the immune response towards a single immunodominant epitope. To determine the effect of a prime/boost vaccination strategy on the clonality of the T-cell response, tVac DCs-primed cultures, known to contain CTLs to sub-dominant epitopes (Fig 4) , were boosted with transfected or peptide-pulsed dendritic cells or monocytes, and their cytotoxicity was tested against PSA-or PAP-peptide pulsed T2 targets. Boosting with antigen-presenting cells (APCs) that express multiple PSA-or PAP-derived epitopes (transfected DCs, or DCs or monocytes pulsed with multiple peptides) restricts the immune response towards one immunodominant epitope (Table 2) , a finding that has already been observed by others. 28 A subdominant T-cell response could only be preserved if boosting is performed with an APC (DC or monocyte) pulsed with the particular subdominant epitope (Table 2; Figure 4 ).
Depletion of CD25 þ cells prior to initial exposure to antigen leads to generation of T cells reactive to both dominant and subdominant epitopes
Subdominant epitopes are generated when dendritic cells are transfected with sVacDCS; however, factors other than TCR signaling such as the CTLA-4/B7 pathway, are contributing to the ineffective proliferation of T cell to subdominant epitopes. 1 Since nonactivating anti-CTLA4 
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antibodies block the suppressor activity of regulatory cells in vitro, 29 we decided to explore the effect of CD25 þ cell depletion prior to priming of peripheral blood T cells with genetically modified autologous dendritic cells. Similar to CTLA-4 inhibition, 1 CD25 þ cell depletion prior to priming with sPSA DCs led to stimulation of T cells reactive to subdominant PSA-derived epitopes. We interpret this as evidence that T-cell responses to subdominant epitopes are generated following priming with sPSA DCs but are inhibited by CD25 þ cells present in the T-cell-enriched fraction (Fig 4) . Both peptidepulsed DCs and peptide-pulsed MCs support development of T-cell effectors in cultures depleted of CD25 þ cells prior to priming with sPSA DCs (Fig 5) .
Addition of CD25 þ cells back to T cells within the first hour of priming with sPSA DCs reverses immunodominance
Suppression of T cells reactive to subdominant epitopes by CD25 þ cells occurs early during T-cell priming. Addition of CD25 þ T cell to T cells that are primed by sPSA DCs is suppressive only if CD4 þ CD25 þ T cells are added within the first hour after initiation of culture (Figs 6 and 7) . No suppression is seen if CD4 þ CD25 þ T cells are added 8 hours after initiation of priming.
sPSA DCs cotransfected with the human GITR-L may support priming and development of T cells reactive to subdominant epitopes Murine CD25 þ T regulatory cells expressed high levels of GITR. We find that human CD4 þ CD25 þ cells also express high levels of GITR in an activation-dependent manner (Fig 8) , similarly to human cytotoxic T cells isolated from tumor lesions. 30 Since signaling through GITR has been found to downregulate the function of T regulatory cells and enhance the development of autoimmunity, 22, 23, 31, 32 we decided to explore the effect of cotransfection of DCs with sPSA and GITR-ligand. In two out of five separate experiments (donors B and C), such DCs primed T cells to the subdominant epitopes (Fig 9) .
Discussion
T cells that are specific for PSA-or PAP-derived peptides exist in the adult male since both sVac DCs and tVacDCs prime T cells that are cytotoxic to LNCaP cells in vitro (Fig 3) . Gene-based vaccination in its current mode of application is effective in breaking tolerance to a self- Figure 4 tVacDCs but not sVacDCs prime T cells that are reactive to subdominant PSA or PAP epitopes. Induction of CTL responses with autologous dendritic cells that have been transfected with either the secreted or truncated version of the human PSA. Peripheral blood mononuclear cells that had been depleted of monocytes were primed with autologous DCs transfected with either sPSA (first column) or tPSA (second and third column). Responding cultures were then boosted with DCs or monocytes pulsed with one of three HLA-A2-restricted PSA-derived peptides (Table 1) and their cytotoxicity was tested against T2 cells pulsed with the same peptide that was used during boosting (PSA 170 -squares; PSA 51 -triangles and PSA 53 -circles). Data points for the control (influenza) peptide are not shown but are identical to those obtained with empty plasmid-transfected DCs (donor A) in all donors tested. Each point represents the mean and SD from three different experiments. Both tPSA DCs-and sPSA DCs-primed T cells are cytotoxic against T2 cells pulsed with PSA 170 peptide. Values for cytotoxicity of either tPSA DCs-or sPSA DCs-primed T cells against T2 targets pulsed with PSA 170 and PSA 51 or PSA 53 peptides were compared. Significant differences at the 30:1 E/T ratio are indicated with xx (Po0.01). Level of cytotoxicity for sPSA DCs primed T cells against T2 cells pulsed with either PSA 51 or PSA 53 for all five donors are identical to controls (T cells primed with empty plasmid-transfected DCs).
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þ cells, GITR-L cotransfection and immunodominance M Mincheff et al Prime (Table 1 ) and their cytotoxicity was tested against T2 cells pulsed with the same peptide that was used during boosting. Each point represents the mean and SD from three different experiments. Values for cytotoxicity of sPSA DCs-primed T cells against T2 targets pulsed with PSA 170 , PSA 51 or PSA 53 peptides were compared. Significant differences at the 30:1 E/T ratio are indicated with xx (Po0.01).
antigen, but the response is narrow and is restricted to few of the potential epitopes. This presents a problem in vaccinology since loss of an MHC haplotype that participates in the conformation of the T-cell antigen, or point mutation in the recognized sequence would result in ineffective immune surveillance. 8, 14, 15, 33 Unlike sVacDCs, tVacDCs prime cytotoxic T cells that are specific for both dominant and subdominant epitopes (Fig 4) . Numerous factors combine to establish an immunodominance hierarchy, 16 among them the ineffective generation and transport of subdominant epitopes by APCs. Since proteasomal degradation is the main source of antigenic fragments destined for MHC presentation, 34 purposeful cytosolic retention of newly synthesized tumor-associated antigens in genetically manipulated APCs increases both the quantity and the diversity of such fragments. Dendritic cells, transfected to synthesize such products, clearly have the advantage to prime to both dominant and subdominant epitopes (Fig 4) . 1 Similarly to boosting with tPSMA-transfected DCs, 1 boosting with polyepitope expressing DCs or monocytes, restricts the immune response to the dominant epitope þ CD25 þ T-cell ratio ¼ 4:1). Responding cultures were then boosted twice with monocytes pulsed with one of three HLA-A2-restricted PSA-derived peptides (PSA 170 -squares; PSA 51 -triangles or PSA 53 -diamonds) and their cytotoxicity was tested against T2 cells pulsed with the same peptide that was used during boosting. Each point represents the mean and SD from three different experiments. Values for cytotoxicity of sPSA DCs-primed T cells against T2 targets pulsed with PSA 170 , PSA 51 or PSA 53 peptides were compared. Significant differences at the 30:1 E/T ratio are indicated with xx (Po0.01).
þ cells, GITR-L cotransfection and immunodominance M Mincheff et al (Table 2 ; Figure 4 ). New vaccines and/or new methods of immunizations need to be developed for those instances. These hopefully will preserve responses to subdominant determinants during reimmunization so that the selection of tumor escape variants that fail to express immunodominant epitopes will be prevented. 8 In a previous study we found that, under conditions that favor priming of T cells to dominant epitopes, CTLA-4 inhibition alleviates immunodominance. Possible operational mechanisms involved CTLA-4 acting as a nonsignaling ''decoy'' receptor reducing the available ligand for CD28 costimulation 35, 36 or creating opportunities for weak signals coming from subdominant epitopes otherwise prompt to inhibition by CTLA-4.
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A third possibility also existed that needed to be explored. 1 Since nonactivating anti-CTLA4 antibodies have been found to block the suppressor activity of regulatory cells in vitro, 29 a possibility existed 38, 39 that a small number of CTLA-4-expressing and -stimulated T cells exerted a suppressive or regulatory effect on other T cells. These cells appeared to be similar if not identical to T regulatory cells. [40] [41] [42] In murine models, suppression of autoreactive T cells has been attributed to a population of spontaneously occurring CD4 þ CD25 þ T cells. 43 Cells with similar phenotype and function have been found in healthy humans. [44] [45] [46] [47] Of interest for cancer immunotherapy is the fact that depleting these cells results in the induction of antitumor immune responses, particularly after tumor-specific vaccination. 48, 49 One hypothesis is that depleting these CD4 þ CD25 þ regulatory T cells in humans enhances a polyclonal T-cell response. 21, 50 Removal of CD25 þ T cells from the T-cell reactive pool prior to priming does result in elimination of immunodominance so that T cells are primed by sVac DCs to both the dominant and the subdominant epitopes (Fig 5) . Similarly to CTLA-4 inhibition,1 CD25 þ cell depletion is effective if performed early during primingactually within the first hour after initiation of culture (Fig 6) . Whether alleviation of immunodominance through CTLA-4 inhibition acts through T regulatory cell suppression needs additional experimentation. One way would be to look whether CD25 þ cell removal and CTLA-4 inhibition have a synergistic effect. A synergism of cytotoxic T lymphocyte-associated antigen 4 blockade þ CD25 þ T cells stained with anti-GITR antibody. FITCconjugated mouse IgG1 was used as a control.
Depletion of CD25
þ cells, GITR-L cotransfection and immunodominance M Mincheff et al and depletion of CD25( þ ) regulatory T cells in antitumor therapy has already been described 51 and this suggests that these interventions may act through different pathways.
Unfortunately, our current experimentation system does not permit quantitative analysis of responses to subdominant epitopes under different conditions. Figure 9 sPSA DCs cotransfected with the human GITR-L may support priming and development of T cells reactive to subdominant epitopes. HLA A2( þ ) peripheral blood mononuclear cells that had been depleted of monocytes were primed with sPSA plasmid-transfected autologous dendritic cells that had (filled in symbols) or had not been (open symbols) transfected with the human GITR-L. Responding cultures were then boosted twice with monocytes pulsed with one of three HLA-A2-restricted PSA-derived peptides (PSA 170 -squares; PSA 51 -triangles or PSA 53 -diamonds) and their cytotoxicity was tested against T2 cells pulsed with the same peptide that was used during boosting. Each point represents the mean and SD from three different experiments. Values for cytotoxicity of sPSA DCs-primed T cells against T2 targets pulsed with PSA 51 or PSA 53 peptides were compared (third column). Significant differences at the 30:1 E/T ratio are indicated with xx (Po0.01; reactivity against PSA 53 for donor B and PSA 51 or PSA 53 for donor C).
þ cells, GITR-L cotransfection and immunodominance M Mincheff et al Finally, the glucocorticoid-induced TNFR (GITR) is expressed at high levels on resting CD4 þ CD25 þ T regulatory cells and regulates their suppressive phenotype. 32 Antibodies to GITR abrogate suppression, demonstrating a functional role for this receptor in regulating the CD4 þ CD25 þ T-cell subset. 22 In our hands, cotransfection of DCs with the natural ligand for GITR leads to T-cell priming to subdominant epitopes in two out of five experiments (Fig 7) . This could be the result of T regulatory cell suppression by GITR signaling. 22, 23, 31, 32 On the other hand, GITR-GITR-L interaction could also provide a costimulatory signal for the antigen-driven proliferation of naive T cells. 52, 53 No matter what the mechanism is, GITR-L coexpression during gene-based vaccination may lead to enhancement of the immune response and alleviation of immunodominance. All of these results, however, have been obtained in an in vitro experimentation system. Additional in vivo experimentation is necessary to validate their significance in immunocompetent hosts.
In conclusion, we have shown that: (1) Dendritic cells transfected with a construct whose product is retained in the cytosol and degraded in the proteasome, prime to both dominant and subdominant epitopes. (2) Early CD25 þ cell depletion during priming in vitro enhances priming to subdominant epitopes. (3) Coexpression of GITR-L during priming may alleviate immunodominance.
